A cationic nanoemulsion for the delivery of next generation RNA vaccines -

Category

Advances in RNA and DNA Delivery

Year

2014

Authors

Luis A. Brito, Michelle Chan, Armin Hekele, Christine A. Shaw, Tom Carsillo, Anja Seubert, Gillis R. Otten, Clayton W. Beard, Antu K. Dey, Anders Lilja, Christian W. Mandl, Susan W. Barnett, Philip R. Dormizer, Jeffrey B. Ulmer, Manmohan Singh, Derek T. O’Hagan, Andrew J. Geall

Institutions

Novartis Vaccines and Diagnostics, Cambridge, MA USA Novartis Vaccines and Diagnostics, Holly Springs, NC USA Novartis Vaccines and Diagnostics, Siena, Italy

Summary

We have reinvented the gene vaccine by creating a synthetic self-replicating RNA vaccine platform capable of providing a rapid immune response to prevent and treat current and emerging infectious threats. We have achieved proof of concept for 1st generation self-replicating RNA vaccines in small and large animal models. The vaccine RNA is produced by an enzymatic transcription reaction and formulated with non-viral delivery systems, thereby avoiding the limitations of cell culture production that complicate production of other vectored delivery systems. Given the many positive attributes of nucleic acid vaccines, our results suggest that a comprehensive evaluation of non-viral technologies to deliver self-amplifying RNA vaccines is warranted.